05:29 PM EDT, 09/29/2025 (MT Newswires) -- Eupraxia Pharmaceuticals ( EPRX ) was last seen up 20% in after-hours New York trading after the company released "positive" results from the highest-dose cohort in the ongoing RESOLVE trial in Eosinophilic Esophagitis.

Data from cohort 9 of the dose escalation part of the study showed that patients receiving an 8 milligram dose per injection experience "rapid and meaningful induction of clinical remission," as measured by the Straumann Dysphagia Index, a tool that assesses difficulty swallowing, according to the statement.

The dose also produced the most significant improvements so far in tissue health, as shown by the Eosinophilic Esophagitis Histological Scoring System, the company added.

Data continues to show a strong correlation between the amount of drug delivered into tissue and the degree of disease resolution, including reductions in eosinophil counts. Long-term results also indicate that patients maintain clinical benefit, tissue health, and tolerability over time, the company said.

"Combined with the absence of any Serious Adverse Events or cases of candidiasis, this strongly suggests that an 8 mg dose per injection is the optimal second dose to test in our phase 2b trial", Chief Executive Officer James Helliwell said.

He added that the company is well-positioned to expand the trial, prepare for a phase 3 program, and explore additional clinical indications, pending discussions with the Food and Drug Administration.

The company also said that it plans to expand the development of EP-104GI, starting with increasing the number of patients in the phase 2b portion of the RESOLVE trial from 60 to at least 120.

The shares were last seen up US$1.14 to US$6.89 after hours. They closed up $0.03 to $8.02 on the Toronto Stock Exchange.